167 related articles for article (PubMed ID: 38791290)
1. Interaction between miR-142-3p and
Dolcetti E; Musella A; Balletta S; Gilio L; Bruno A; Stampanoni Bassi M; Lauritano G; Buttari F; Fresegna D; Tartacca A; Mariani F; Palmerio F; Rovella V; Ferese R; Gambardella S; Giardina E; Finardi A; Furlan R; Mandolesi G; Centonze D; De Vito F
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791290
[TBL] [Abstract][Full Text] [Related]
2. MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis.
De Vito F; Musella A; Fresegna D; Rizzo FR; Gentile A; Stampanoni Bassi M; Gilio L; Buttari F; Procaccini C; Colamatteo A; Bullitta S; Guadalupi L; Caioli S; Vanni V; Balletta S; Sanna K; Bruno A; Dolcetti E; Furlan R; Finardi A; Licursi V; Drulovic J; Pekmezovic T; Fusco C; Bruzzaniti S; Hornstein E; Uccelli A; Salvetti M; Matarese G; Centonze D; Mandolesi G
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12765. PubMed ID: 34490928
[TBL] [Abstract][Full Text] [Related]
3. miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation.
Mandolesi G; De Vito F; Musella A; Gentile A; Bullitta S; Fresegna D; Sepman H; Di Sanza C; Haji N; Mori F; Buttari F; Perlas E; Ciotti MT; Hornstein E; Bozzoni I; Presutti C; Centonze D
J Neurosci; 2017 Jan; 37(3):546-561. PubMed ID: 28100738
[TBL] [Abstract][Full Text] [Related]
4. BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression.
Nociti V; Santoro M; Quaranta D; Losavio FA; De Fino C; Giordano R; Palomba NP; Rossini PM; Guerini FR; Clerici M; Caputo D; Mirabella M
PLoS One; 2018; 13(10):e0206140. PubMed ID: 30352103
[TBL] [Abstract][Full Text] [Related]
5. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study.
Sağır F; Ersoy Tunalı N; Tombul T; Koral G; Çırak S; Yılmaz V; Türkoğlu R; Tüzün E
Genet Test Mol Biomarkers; 2021 Nov; 25(11):720-726. PubMed ID: 34788141
[No Abstract] [Full Text] [Related]
6. MiR-142-3p is a Critical Modulator of TNF-mediated Neuronal Toxicity in Multiple Sclerosis.
De Vito F; Balletta S; Caioli S; Musella A; Guadalupi L; Vanni V; Fresegna D; Bassi MS; Gilio L; Sanna K; Gentile A; Bruno A; Dolcetti E; Buttari F; Pavone L; Furlan R; Finardi A; Perlas E; Hornstein E; Centonze D; Mandolesi G
Curr Neuropharmacol; 2023; 21(12):2567-2582. PubMed ID: 37021418
[TBL] [Abstract][Full Text] [Related]
7. BDNF Val66Met polymorphism and brain volumes in multiple sclerosis.
Dinacci D; Tessitore A; Russo A; De Bonis ML; Lavorgna L; Picconi O; Sacco R; Bonavita S; Gallo A; Servillo G; Marcuccio L; Comerci M; Galletti P; Alfano B; Tedeschi G
Neurol Sci; 2011 Feb; 32(1):117-23. PubMed ID: 20953813
[TBL] [Abstract][Full Text] [Related]
8. The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis.
Dolcetti E; Bruno A; Azzolini F; Gilio L; Moscatelli A; De Vito F; Pavone L; Iezzi E; Gambardella S; Giardina E; Ferese R; Buttari F; Rizzo FR; Furlan R; Finardi A; Musella A; Mandolesi G; Guadalupi L; Centonze D; Stampanoni Bassi M
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205376
[TBL] [Abstract][Full Text] [Related]
9. Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study.
Gonzalez-Martinez A; Bose G; Lokhande H; Saxena S; Healy BC; Polgar-Turcsanyi M; Weiner HL; Chitnis T
J Neuroinflammation; 2023 Jun; 20(1):136. PubMed ID: 37264432
[TBL] [Abstract][Full Text] [Related]
10. BDNF VAL66MET Polymorphism Elevates the Risk of Bladder Cancer via MiRNA-146b in Micro-Vehicles.
Li C; Zeng X; Liu Z; Li F; Wang K; Wu B
Cell Physiol Biochem; 2018; 45(1):366-377. PubMed ID: 29402794
[TBL] [Abstract][Full Text] [Related]
11. Peripheral BDNF correlated with miRNA in BD-II patients.
Lee SY; Wang TY; Lu RB; Wang LJ; Chang CH; Chiang YC; Tsai KW
J Psychiatr Res; 2021 Apr; 136():184-189. PubMed ID: 33610945
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis.
Rossi S; Studer V; Motta C; Germani G; Macchiarulo G; Buttari F; Mancino R; Castelli M; De Chiara V; Weiss S; Martino G; Furlan R; Centonze D
J Neuroinflammation; 2014 Feb; 11():32. PubMed ID: 24548694
[TBL] [Abstract][Full Text] [Related]
13. Depression in multiple sclerosis: effect of brain derived neurotrophic factor Val66Met polymorphism and disease perception.
Santoro M; Nociti V; De Fino C; Caprara A; Giordano R; Palomba N; Losavio F; Marra C; Patanella AK; Mirabella M; Gainotti G; Quaranta D
Eur J Neurol; 2016 Mar; 23(3):630-40. PubMed ID: 26756166
[TBL] [Abstract][Full Text] [Related]
14. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor.
Zivadinov R; Weinstock-Guttman B; Benedict R; Tamaño-Blanco M; Hussein S; Abdelrahman N; Durfee J; Ramanathan M
Hum Mol Genet; 2007 Nov; 16(22):2659-68. PubMed ID: 17656372
[TBL] [Abstract][Full Text] [Related]
15. Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis.
Soares JL; Oliveira EM; Pontillo A
Mult Scler Relat Disord; 2019 Apr; 29():26-34. PubMed ID: 30658261
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of the BDNF gene show neither association with multiple sclerosis susceptibility nor clinical course.
Mero IL; Smestad C; Lie BA; Lorentzen ÅR; Sandvik L; Landrø NI; Aarseth JH; Myhr KM; Celius EG; Harbo HF
J Neuroimmunol; 2012 Mar; 244(1-2):107-10. PubMed ID: 22341604
[TBL] [Abstract][Full Text] [Related]
17. The BDNF-Val66Met polymorphism: implications for susceptibility to multiple sclerosis and severity of disease.
Lindquist S; Schott BH; Ban M; Compston DA; Sawcer S; Sailer M
J Neuroimmunol; 2005 Oct; 167(1-2):183-5. PubMed ID: 16046000
[TBL] [Abstract][Full Text] [Related]
18. No association of the Val66Met polymorphism of brain-derived neurotrophic factor (BDNF) to multiple sclerosis.
Blanco Y; Gómez-Choco M; Arostegui JL; Casanova B; Martínez-Rodríguez JE; Boscá I; Munteis E; Yagüe J; Graus F; Saiz A
Neurosci Lett; 2006 Apr; 396(3):217-9. PubMed ID: 16356643
[TBL] [Abstract][Full Text] [Related]
19. Gas6/TAM system as potential biomarker for multiple sclerosis prognosis.
D'Onghia D; Colangelo D; Bellan M; Tonello S; Puricelli C; Virgilio E; Apostolo D; Minisini R; Ferreira LL; Sozzi L; Vincenzi F; Cantello R; Comi C; Pirisi M; Vecchio D; Sainaghi PP
Front Immunol; 2024; 15():1362960. PubMed ID: 38745659
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
